← Evidence map

ArticleDrugs in R&D2026

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies.

HeeJae Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

2 trials

NCT05718843phase 136 enrolled2023 NCT05731895phase 129 enrolled2023

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies. | Socratic